Literature DB >> 2451963

Relationship between extracellular 5-hydroxytryptamine and behaviour following monoamine oxidase inhibition and L-tryptophan.

A J Sleight1, C A Marsden, K F Martin, M G Palfreyman.   

Abstract

1. The present study investigates the effects of selective and a non-selective monoamine oxidase (MAO) inhibitors combined with L-tryptophan on MAO-A and -B activity, hypothalamic extracellular 5-hydroxytryptamine (5-HT) in vivo and the occurrence of the 5-HT behavioural syndrome. 2. Selective inhibition of intraneuronal MAO-A with MDL 72394 (0.5 mg kg-1, i.p.) had no effect on extracellular 5-HT and following administration of L-tryptophan (50 mg kg-1, i.p.) the 5-HT behavioural syndrome was not induced. 3. Selective inhibition of MAO-A at all sites with clorgyline (5 mg kg-1, i.p.) increased extracellular 5-HT but did not induce the 5-HT behavioural syndrome when combined with L-tryptophan administration. 4. Selective inhibition of MAO-B with selegiline (10 mg kg-1, i.p.) had no effect on extracellular 5-HT and the 5-HT behavioural syndrome was not observed after L-tryptophan administration. 5. Inhibition of MAO-A and -B with a higher and therefore non-selective, dose of MDL 72394 (2 mg kg-1) markedly increased extracellular 5-HT but failed to induce the 5-HT behavioural syndrome after L-tryptophan administration. 6. Inhibition of MAO-A and -B at all sites in the brain (tranylcypromine 20 mg kg-1, i.p. or clorgyline 5 mg kg-1 plus selegiline 10 mg kg-1) increased extracellular 5-HT and induced the behavioural syndrome on administration of L-tryptophan. 7. The results demonstrate that inhibition of MAO-A and -B both within amine neurones and elsewhere in the brain is essential for the development of the 5-HT behavioural syndrome. Whilst the syndrome is associated with increased extracellular 5-HT this does not appear necessarily to result in the syndrome and may indicate that increased extracellular 5-HT is not solely involved in the induction of the '5-HT behavioural syndrome'. Whilst the syndrome is associated with increased extracellular 5-HT this does not appear necessarily to result in the syndrome and may indicate that increased extracellular 5-HT is not solely involved in the induction of the '5-HT behavioural syndrome'.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2451963      PMCID: PMC1853803          DOI: 10.1111/j.1476-5381.1988.tb11435.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  21 in total

1.  The role of tryptamine in the behavioural effects of tranylcypromine + L-tryptophan.

Authors:  C A Marsden; G Curzon
Journal:  Neuropharmacology       Date:  1979-02       Impact factor: 5.250

Review 2.  Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine.

Authors:  A R Green; D G Grahame-Smith
Journal:  Nature       Date:  1976-04-08       Impact factor: 49.962

3.  Deamination of 5-hydroxytryptamine by both forms of monoamine oxidase in the rat brain.

Authors:  C J Fowler; K F Tipton
Journal:  J Neurochem       Date:  1982-03       Impact factor: 5.372

4.  Single and repeated administration of neuroleptic drugs to rats: effects on striatal dopamine-sensitive adenylate cyclase and locomotor activity produced by tranylcypromine and L-tryptophan or L-Dopa.

Authors:  D J Heal; A R Green; D J Boullin; D G Grahame-Smith
Journal:  Psychopharmacology (Berl)       Date:  1976-09-29       Impact factor: 4.530

5.  MDL 72145, an enzyme-activated irreversible inhibitor with selectivity for monoamine oxidase type B.

Authors:  M Zreika; I A McDonald; P Bey; M G Palfreyman
Journal:  J Neurochem       Date:  1984-08       Impact factor: 5.372

6.  The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat.

Authors:  M D Tricklebank; C Forler; J R Fozard
Journal:  Eur J Pharmacol       Date:  1984-11-13       Impact factor: 4.432

7.  Tryptamine: a neuromodulator or neurotransmitter in mammalian brain?

Authors:  R S Jones
Journal:  Prog Neurobiol       Date:  1982       Impact factor: 11.685

8.  Increased total activity in the rat after L-tryptophan plus the monoamine oxidase-A inhibitor amiflamine but not after L-tryptophan plus clorgyline.

Authors:  T Archer; C J Fowler; A Fredriksson; T Lewander; O Magnusson; B Mohringe; U Söderberg
Journal:  Br J Pharmacol       Date:  1985-07       Impact factor: 8.739

9.  The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-DOPA to rats.

Authors:  J F Deakin; A R Green
Journal:  Br J Pharmacol       Date:  1978-10       Impact factor: 8.739

10.  Changes in monoamine metabolites measured by simultaneous in vivo differential pulse voltammetry and intracerebral dialysis.

Authors:  T Sharp; N T Maidment; M P Brazell; T Zetterström; U Ungerstedt; G W Bennett; C A Marsden
Journal:  Neuroscience       Date:  1984-08       Impact factor: 3.590

View more
  10 in total

1.  Effect of milacemide on extracellular and tissue concentrations of dopamine and 5-hydroxytryptamine in rat frontal cortex.

Authors:  J Semba; M Doheny; P N Patsalos; G Sarna; G Curzon
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

2.  Proceedings of the British Pharmacological Society Meeting. 3rd-5th January 1990. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1990-04       Impact factor: 8.739

3.  Proceedings of the British Pharmacological Society Meeting. Sheffield, 18-20th April 1990.

Authors: 
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

4.  Concurrent determination of effects of p-chloroamphetamine on central extracellular 5-hydroxytryptamine concentration and behaviour.

Authors:  P H Hutson; G Curzon
Journal:  Br J Pharmacol       Date:  1989-04       Impact factor: 8.739

5.  Monoamine oxidase inhibitors increase preferentially extracellular 5-hydroxytryptamine in the midbrain raphe nuclei. A brain microdialysis study in the awake rat.

Authors:  P Celada; F Artigas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-06       Impact factor: 3.000

6.  In vivo evidence for the reversible action of the monoamine oxidase inhibitor brofaromine on 5-hydroxytryptamine release in rat brain.

Authors:  N Bel; F Artigas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-05       Impact factor: 3.000

7.  Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline.

Authors:  Z Speiser; T Fine; L Litinetsky; S Eliash; E Blaugrund; S Cohen
Journal:  J Neural Transm (Vienna)       Date:  2007-09-07       Impact factor: 3.575

8.  Modulation by drugs of the release of total tritium and 3H-5-HT from rat hypothalamic slices.

Authors:  C Moret; M Briley
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-05       Impact factor: 3.000

9.  Isolation rearing of rats alters release of 5-hydroxytryptamine and dopamine in the frontal cortex: an in vivo electrochemical study.

Authors:  F Crespi; I K Wright; C Möbius
Journal:  Exp Brain Res       Date:  1992       Impact factor: 1.972

10.  The metabolic fate of infused L-tryptophan in men: possible clinical implications of the accumulation of circulating tryptophan and tryptophan metabolites.

Authors:  G Heuther; G Hajak; A Reimer; B Poeggeler; M Blömer; A Rodenbeck; E Rüther
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.